Zhao Ming-Ming, Zhang Yu, Li Liu-Sheng, Yu Zi-Kai, Li Bo
Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China.
Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing Institute of Traditional Chinese Medicine, Beijing 100010, China.
Ann Transl Med. 2017 Mar;5(6):136. doi: 10.21037/atm.2017.01.17.
To evaluate the efficacy and safety of Danggui Buxue Decoction for renal anemia when combined with western medicine treatment of anemia.
Electronic searching Medline, Embase, Web of Science, Cochrane Library, Chinese BioMedical Literature Database (CBM), China National Knowledge Infrastructure (CNKI), WanFang data, Chinese Sci-tech periodical full-text database (VIP). Randomized controlled trials reported results of efficacy and safety of Danggui Buxue Decoction in combination with western medicine treatment of anemia for renal anemia. The "risk of bias assessment tool (Version 5.1.0)" of Cochrane Handbook was applied to assess the quality of included trials and RevMan 5.3 software was used for data analysis.
A total of 111 studies was retrieved, seven studies including 460 cases were included, the methodological quality of included trials was poor. The result of meta-analysis demonstrated that there was no difference in hemoglobin (Hb) [weighted mean differences (WMD) =-8.75, 95% confidence interval (CI): (-18.64, 1.13), P=0.08], whereas the subgroup analysis showed the difference was significant when the ratio of Radix Astragali to Radix Angelicae Sinensis was 5:1 [WMD =-16.27, 95% CI: (-28.73, -3.80), P=0.01], increase of Hb was more effective in experimental group than control group and the difference was not significant when the ratio of Radix Astragali to Radix Angelicae Sinensis was 5≠1 [WMD =-0.57, 95% CI: (-4.52, 3.39), P=0.78]. There were significant differences in red blood cell (RBC) [WMD =-0.49, 95% CI: (-0.69, -0.28), P<0.00001], hematocrit (HCT) [WMD =-1.92, 95% CI: (-3.15, -0.69), P=0.002] and clinical efficacy [odd ratio (OR) =0.30, 95% CI: (0.13, 0.69), P=0.004] between Danggui Buxue Decoction combination group and control group, the experimental group was better than control group. There was no adverse event reported in the experimental group.
Danggui Buxue Decoction in combination with conventional western medicine (CWM) for renal anemia might be superior to CWM alone and there was no adverse event in the experimental group, it might be more effective when the ratio of Radix Astragali to Radix Angelicae Sinensis was 5:1. However, the quality of included studies was not high, and less attention was paid to the safety, high quality randomized controlled trials are needed to further confirm the findings.
评估当归补血汤联合西药治疗肾性贫血的疗效和安全性。
电子检索Medline、Embase、Web of Science、Cochrane图书馆、中国生物医学文献数据库(CBM)、中国知网(CNKI)、万方数据、中文科技期刊全文数据库(VIP)。随机对照试验报告了当归补血汤联合西药治疗肾性贫血的疗效和安全性结果。应用Cochrane手册的“偏倚风险评估工具(5.1.0版)”评估纳入试验的质量,并使用RevMan 5.3软件进行数据分析。
共检索到111项研究,纳入7项研究共460例,纳入试验的方法学质量较差。Meta分析结果显示,血红蛋白(Hb)差异无统计学意义[加权均数差(WMD)=-8.75,95%置信区间(CI):(-18.64,1.13),P=0.08],而亚组分析显示,当黄芪与当归比例为5∶1时差异有统计学意义[WMD=-16.27,95%CI:(-28.73,-3.80),P=0.01],试验组Hb升高效果优于对照组;当黄芪与当归比例不为5∶1时差异无统计学意义[WMD=-0.57,95%CI:(-4.52,3.39),P=0.78]。当归补血汤联合组与对照组在红细胞(RBC)[WMD=-0.49,95%CI:(-0.69,-0.28),P<0.00001]、血细胞比容(HCT)[WMD=-1.92,95%CI:(-3.15,-0.69),P=0.002]和临床疗效[比值比(OR)=0.30,95%CI:(0.13,0.69),P=0.004]方面差异有统计学意义,试验组优于对照组。试验组未报告不良事件。
当归补血汤联合传统西药治疗肾性贫血可能优于单纯西药治疗,且试验组无不良事件,当黄芪与当归比例为5∶1时可能更有效。然而,纳入研究的质量不高,对安全性的关注较少,需要高质量的随机对照试验进一步证实该结果。